| Literature DB >> 23181832 |
George L Wehby1, Norman Goco, Danilo Moretti-Ferreira, Temis Felix, Antonio Richieri-Costa, Carla Padovani, Fernanda Queiros, Camilla Vila Nova Guimaraes, Rui Pereira, Steve Litavecz, Tyler Hartwell, Hrishikesh Chakraborty, Lorette Javois, Jeffrey C Murray.
Abstract
BACKGROUND: Oral clefts are one of the most common birth defects with significant medical, psychosocial, and economic ramifications. Oral clefts have a complex etiology with genetic and environmental risk factors. There are suggestive results for decreased risks of cleft occurrence and recurrence with folic acid supplements taken at preconception and during pregnancy with a stronger evidence for higher than lower doses in preventing recurrence. Yet previous studies have suffered from considerable design limitations particularly non-randomization into treatment. There is also well-documented effectiveness for folic acid in preventing neural tube defect occurrence at 0.4 mg and recurrence with 4 mg. Given the substantial burden of clefting on the individual and the family and the supportive data for the effectiveness of folic acid supplementation as well as its low cost, a randomized clinical trial of the effectiveness of high versus low dose folic acid for prevention of cleft recurrence is warranted. METHODS/Entities:
Mesh:
Substances:
Year: 2012 PMID: 23181832 PMCID: PMC3532199 DOI: 10.1186/1471-2431-12-184
Source DB: PubMed Journal: BMC Pediatr ISSN: 1471-2431 Impact factor: 2.125